Pembrolizumab in HER2-Positive Gastric Cancer

被引：21

作者：

Janjigian, Yelena Y. ^{[1
]}

Kawazoe, Akihito ^{[2
]}

Bai, Yuxian ^{[3
]}

Xu, Jianming ^{[4
]}

Lonardi, Sara ^{[5
]}

Metges, Jean Phillipe ^{[6
]}

Yanez, Patricio ^{[7
]}

Wyrwicz, Lucjan S. ^{[8
]}

Shen, Lin ^{[9
]}

Ostapenko, Yuriy ^{[10
]}

Bilici, Mehmet ^{[11
]}

Chung, Hyun Cheol ^{[12
]}

Shitara, Kohei

Qin, Shukui ^{[13
]}

Van Cutsem, Eric ^{[14
]}

Tabernero, Josep ^{[15
]}

Luo, Suxia ^{[16
]}

Mahave, Mauricio ^{[17
]}

Tang, Yong ^{[18
]}

Lowery, Maeve ^{[19
]}

Monteiro, Maria M. F. ^{[20
]}

Xu, Linzhi ^{[21
]}

Shih, Chie-Schin ^{[21
]}

Sharan, Kanu P. ^{[21
]}

Bhagia, Pooja ^{[21
]}

Rha, Sun Young ^{[12
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10029 USA

[2] Natl Canc Hosp East, Kashiwa, Japan

[3] Harbin Med Univ Canc Hosp, Harbin, Peoples R China

[4] Fifth Med Ctr Peoples Liberat Army, Beijing, Peoples R China

[5] Ist Oncol Veneto, Padua, Italy

[6] Univ Hosp Brest, Brest, France

[7] James Lind Canc Res Ctr, Temuco, Chile

[8] Maria Sklodowska Curie Natl Canc Res Inst, Warsaw, Poland

[9] Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China

[10] Natl Canc Inst, Kiev, Ukraine

[11] Ataturk Univ, Erzurum, Turkiye

[12] Yonsei Canc Ctr, Seoul, South Korea

[13] Canc Ctr Peoples Liberat Army, Nanjing, Peoples R China

[14] Univ Hosp Gasthuisberg, Leuven, Belgium

[15] Vall dHebron Univ Hosp, Inst Oncol, Barcelona, Spain

[16] Henan Canc Hosp, Zhengzhou, Peoples R China

[17] Fdn Arturo Lopez Perez, Santiago, Chile

[18] Xinjiang Med Univ, Canc Hosp, Urumqi, Peoples R China

[19] Trinity St Jamess Canc Inst, Dublin, Ireland

[20] Inst Canc Ceara, Fortaleza, CE, Brazil

[21] Merck, Rahway, NJ USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2024年

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1056/NEJMc2408121

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pembrolizumab in HER2-Positive Gastric Cancer The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy alone.

引用

页数：3

共 2 条

[1] Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial [J].

Janjigian, Yelena Y. ;

Kawazoe, Akihito ;

Bai, Yuxian ;

Xu, Jianming ;

Lonardi, Sara ;

Metges, Jean Phillipe ;

Yanez, Patricio ;

Wyrwicz, Lucjan S. ;

Shen, Lin ;

Ostapenko, Yuriy ;

Bilici, Mehmet ;

Chung, Hyun Cheol ;

Shitara, Kohei ;

Qin, Shu-Kui ;

Van Cutsem, Eric ;

Tabernero, Josep ;

Li, Kan ;

Shih, Chie-Schin ;

Bhagia, Pooja ;

Rha, Sun Young .

LANCET, 2023, 402 (10418) :2197-2208

[2] The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer [J].

Janjigian, Yelena Y. ;

Kawazoe, Akihito ;

Yanez, Patricio ;

Li, Ning ;

Lonardi, Sara ;

Kolesnik, Oleksii ;

Barajas, Olga ;

Bai, Yuxian ;

Shen, Lin ;

Tang, Yong ;

Wyrwicz, Lucjan S. ;

Xu, Jianming ;

Shitara, Kohei ;

Qin, Shukui ;

Van Cutsem, Eric ;

Tabernero, Josep ;

Li, Lie ;

Shah, Sukrut ;

Bhagia, Pooja ;

Chung, Hyun Cheol .

NATURE, 2021, 600 (7890) :727-+

← 1 →